Table 5.
Postoperative recurrence and adjuvant therapy.
| Patients (n = 29) | |
|---|---|
| Time of postoperative follow-up (months), median (IQR) | 10.3 (9.1–13.2) |
| Number of patients received adjuvant therapy, n (%) | 27 (93.1%) |
| LEN + CAM | 14 (48.3%) |
| TACE + LEN + CAM | 6 (20.7%) |
| CAM | 3 (10.3%) |
| TACE + CAM | 2 (6.9%) |
| TACE + LEN | 1 (3.4%) |
| TACE + Penpulimab | 1 (3.4%) |
| Adjuvant therapy cycles, median (IQR) | 2 (1–4) |
| Number of patients with HCC recurrence, n (%) | 4 (13.8%) |
| Intrahepatic | 3 (10.3%) |
| Pulmonary | 1 (3.4%) |
| Time of recurrence (months) | 3.3, 3.4, 3.8, and 6.3 |
CAM, camrelizumab; LEN, lenvatinib; TACE, transcatheter arterial chemoembolisation; HCC, hepatocellular carcinoma.